ALN-CC5, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MYASTHENIA GRAVIS: INTERIM PHASE 1 DATA IN HEALTHY VOLUNTEERS AND EFFICACY IN PRECLINICAL ANIMAL MODELS OF MG.

Borodovsky A.; Kawahata N.; Mclean H.; Partisano A.; Kim J.; Najafian N.; Kusner Linda; Kaminski Henry; Taubel Jorg; Bush Jim

首页> 外文期刊>Muscle and Nerve >ALN-CC5, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MYASTHENIA GRAVIS: INTERIM PHASE 1 DATA IN HEALTHY VOLUNTEERS AND EFFICACY IN PRECLINICAL ANIMAL MODELS OF MG.

【24h】

ALN-CC5, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MYASTHENIA GRAVIS: INTERIM PHASE 1 DATA IN HEALTHY VOLUNTEERS AND EFFICACY IN PRECLINICAL ANIMAL MODELS OF MG.

机译：ALN-CC5，一种用于治疗重症肌无力的研究性RNAi疗法：MG的临床前动物模型中健康志愿者的第一阶段中期数据和疗效。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Muscle and Nerve》 |2016年第3期|共1页
作者
Borodovsky A.; Kawahata N.; Mclean H.; Partisano A.; Kim J.; Najafian N.; Kusner Linda; Kaminski Henry; Taubel Jorg; Bush Jim;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类人体生理学;
关键词

相似文献

外文文献
中文文献
专利

1. ALN-CC5, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MYASTHENIA GRAVIS: INTERIM PHASE 1 DATA IN HEALTHY VOLUNTEERS AND EFFICACY IN PRECLINICAL ANIMAL MODELS OF MG. [J] . Borodovsky A., Kawahata N., Mclean H., Muscle and Nerve . 2016,第3期

机译：ALN-CC5，一种用于治疗重症肌无力的研究性RNAi疗法：MG的临床前动物模型中健康志愿者的第一阶段中期数据和疗效。
2. Editorial: Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis [J] . Kusner Linda L., Kaminski Henry J. Experimental Neurology . 2015,第Null期

机译：社论：重症肌无力动物模型临床前评价标准化的特刊
3. PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY [J] . Adams D., Coelho T., Conceicao E., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Patisiran的第2阶段开放标签延伸（OLE）研究，一种调查RNA干扰（RNAi）治疗遗传性遗传素邻近的遗传素
4. Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis [O] . Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, 2019

机译：靶向C5的研究性RNAi治疗在重症肌无力的临床前模型中有效
5. Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [O] . 2015

机译：Revusiran的2期开放标签扩展（OLE）研究，一种研究性RNAi治疗药物，用于治疗甲状腺甲状腺素转基因蛋白淀粉样变性病

ALN-CC5, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF MYASTHENIA GRAVIS: INTERIM PHASE 1 DATA IN HEALTHY VOLUNTEERS AND EFFICACY IN PRECLINICAL ANIMAL MODELS OF MG.

著录项

相似文献

相关主题

期刊订阅